PD-1/PD-L1 inhibitors + Chemotherapy
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Borderline Resectable Carcinoma
Conditions
Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Immune Checkpoint Inhibitor, Chemotherapy, Radiotherapy, Tislelizumab
Trial Timeline
Nov 1, 2025 → Nov 1, 2028
NCT ID
NCT07339488About PD-1/PD-L1 inhibitors + Chemotherapy
PD-1/PD-L1 inhibitors + Chemotherapy is a phase 2 stage product being developed by BeOne Medicines for Borderline Resectable Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT07339488. Target conditions include Borderline Resectable Carcinoma, Unresectable Cancer, Esophageal Squamous Cell Carcinoma (ESCC).
What happened to similar drugs?
0 of 4 similar drugs in Borderline Resectable Carcinoma were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07339488 | Phase 2 | Active |
Competing Products
12 competing products in Borderline Resectable Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine + placebo | Eli Lilly | Phase 3 | 40 |
| olanzapine | Eli Lilly | Pre-clinical | 26 |
| Olanzapine | Eli Lilly | Phase 3 | 40 |
| Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate | Jiangsu Hengrui Medicine | Phase 2 | 31 |
| Durvalumab + Tremelimumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 27 |
| quetiapine extended-release + Placebo | AstraZeneca | Phase 3 | 40 |
| Quetiapine fumarate + Placebo | AstraZeneca | Phase 2 | 35 |
| Quetiapine Fumarate | AstraZeneca | Phase 3 | 40 |
| ziprasidone + Placebo | Pfizer | Phase 2 | 35 |
| Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin | Bristol Myers Squibb | Phase 1 | 29 |
| Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab | Arcus Biosciences | Phase 1/2 | 33 |
| vafidemstat + Placebo | Oryzon Genomics | Phase 2 | 25 |